Brief: Vectivbio Receives FDA Orphan Drug Designation For Apraglutide For Acute Graft-Versus-Host Disease
24/06/2021 12:35
June 24 (Reuters) - VectivBio Holding AG VECT.O :
* VECTIVBIO RECEIVES FDA ORPHAN DRUG DESIGNATION FOR
APRAGLUTIDE
FOR ACUTE GRAFT-VERSUS-HOST DISEASE
* VECTIVBIO HOLDING AG - PLANS TO INITIATE PHASE 2 TRIAL
EVALUATING APRAGLUTIDE FOR TREATMENT OF AGVHD IN Q1 OF 2022
Source text for Eikon: ID:nGNX7vDnM7
Further company coverage: VECT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VectivBio Holding AG
See all newsBrief: Ironwood And VectivBio Announce Expiration Of Hart-Scott-Rodino Waiting Period For Proposed Acquisition Of VectivBio
Brief: Ironwood Pharmaceuticals Says If Deal Aborts, VectivBio To Pay Termination Fee
U.S. STOCKS ON THE MOVE-Pfizer, Zoom Video, American Airlines
U.S. STOCKS ON THE MOVE-Atea Pharma, Microbot Medical, Krystal
U.S. STOCKS ON THE MOVE-NuScale Power Corp, Foot Locker, Greenhill